Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
McKinsey
AstraZeneca
Express Scripts
Johnson and Johnson

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Details for Patent: RE37838

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: RE37838
Title: Composition for contraception
Abstract:A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17.beta.-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from .[.0.25 to 0.30 mg of.]. drospirenone and .[.0.1 to 0.2 mg of.]. cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
Inventor(s): Spona; Jurgen (Vienna, AT), Dusterberg; Bernd (Berlin, DE), Ludicke; Frank (Geneva, CH)
Assignee: Schering Aktiengesellschaft (DE)
Application Number:09/504,084
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE37838
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent RE37838

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE37838

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany4344462Dec 22, 1993

International Family Members for US Patent RE37838

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 344038   Start Trial
Canada 2179728   Start Trial
China 100377713   Start Trial
China 1142185   Start Trial
China 1611222   Start Trial
Czech Republic 296387   Start Trial
Czech Republic 9601861   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Harvard Business School
Moodys
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.